Skip to main content

Table 1 Patient characteristics

From: Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study

 

DCS-first group

PCB-first group

Total

N (Male/Female)

17 (10/7)

19 (12/7)

36 (22/14)

Age (years)

48.4 ± 16.1

40.1 ± 10.7

44.0 ± 14.0

Age at onset (years)

22.6 ± 8.5

24.3 ± 5.6

23.5 ± 7.1

Age at starting therapy (years)

23.9 ± 8.5

24.8 ± 5.7

24.4 ± 7.1

Duration of illness (years)

25.8 ± 17.3

15.8 ± 9.2

20.5 ± 14.4

Education (years)

12.4 ± 2.6

13.9 ± 2.9

13.2 ± 2.9

CPZ equivalents (mg/day)

777.5 ± 614.8

871.3 ± 618.0

827.0 ± 609.5

  1. DCS D-cycloserine, PCB placebo, CPZ chlorpromazine. No significant difference was noted between the DCS-first and PCB-first groups on age, age at onset, age at starting therapy, duration of illness, education, or CPZ equivalents